---
id: 123
title: Cryptococcus and Cryptococcal Meningitis
category: organisms
subcategory: fungi
tags: [Cryptococcus, meningitis, cryptococcoma, amphotericin-B, flucytosine, India-ink]
difficulty: medium
---

## Question

How is cryptococcal meningitis managed? Use the **"Amphotericin B + Flucytosine (Induction) → Fluconazole (Consolidation/Maintenance)"** framework.

## Answer

### **Cryptococcus Overview:**

**Species:**
- ***Cryptococcus neoformans*:** Most common, **HIV/AIDS** (CD4 <100), bird droppings (pigeons)
- ***Cryptococcus gattii*:** Immunocompetent, **Pacific Northwest**, eucalyptus trees, **more severe CNS disease**

**Clinical Syndromes:**
- **Meningitis** (most common)
- **Pulmonary** (nodules, infiltrates)
- **Disseminated** (skin, bone, prostate)

### **Cryptococcal Meningitis Treatment:**

**Induction Therapy (2 weeks):**
- **Liposomal amphotericin B** 3-4 mg/kg IV daily (or **amphotericin B deoxycholate** 0.7-1 mg/kg daily)
- **+**
- **Flucytosine** 100 mg/kg/day PO divided q6h (25 mg/kg q6h)

**Consolidation Therapy (8 weeks):**
- **Fluconazole** 400mg PO daily × 8 weeks

**Maintenance Therapy (Suppressive):**
- **Fluconazole** 200mg PO daily
- **Duration (HIV):** Until immune reconstitution (CD4 >200 × 6 months + undetectable VL on ART)
- **Duration (non-HIV):** ≥12 months (lifelong if ongoing immunosuppression)

### **Increased Intracranial Pressure (ICP) Management:**

**Critical Component:**
- **Opening pressure ≥25 cm H2O:** **Therapeutic LP** (remove CSF to reduce pressure to <20 cm H2O or remove 20-30 mL)
- **Repeat LPs daily** if persistently elevated ICP
- **Temporary lumbar drain** if refractory
- **VP shunt** (last resort, high failure rates)

**Avoid:**
- **Corticosteroids** (worsen outcomes)
- **Acetazolamide** (no proven benefit, may worsen)
- **Mannitol** (no proven benefit)

## Key Points

### **Diagnosis:**

**CSF Analysis:**
- **Opening pressure:** Often ↑↑ (>25 cm H2O) - **measure in ALL patients**
- **Cell count:** **Lymphocytic pleocytosis** (often low, 20-200 cells/μL) OR **no pleocytosis** (HIV)
- **Protein:** Mildly elevated
- **Glucose:** Low or normal

**Cryptococcal Antigen (CrAg):**
- **Serum or CSF CrAg:** **Highly sensitive** (>95%), **highly specific**
- **Gold standard** for diagnosis
- **Titer useful:** High titers (>1:1024) → worse prognosis, monitor for treatment response

**Other Tests:**
- **India ink stain:** **50-80% sensitive** (encapsulated yeast), less sensitive than CrAg
- **Culture:** CSF, blood (gold standard for speciation, but slower)

### **Flucytosine (5-FC):**
- **Mechanism:** Converted to 5-FU (inhibits RNA/DNA synthesis)
- **Synergy** with amphotericin B
- **Adverse effects:** Bone marrow suppression (monitor CBC), hepatotoxicity, GI
- **TDM:** Target peak **50-100 mcg/mL** (2h post-dose)
- **Often unavailable** in resource-limited settings

### **HIV-Associated Cryptococcal Meningitis:**
- **Screen all HIV patients** with CD4 <100 (serum CrAg)
- **Preemptive therapy** if asymptomatic CrAg+ (fluconazole 800mg × 2 weeks → 400mg × 8 weeks → 200mg maintenance)
- **Start ART:** **After 4-6 weeks** of antifungal therapy (reduces IRIS risk)
- **IRIS:** Can occur 2-12 weeks after starting ART (increased inflammation, worsening symptoms)

### **Cryptococcoma:**
- **Mass lesion** in brain (single or multiple)
- **Management:** **Same antifungal therapy** as meningitis + **consider surgery** if large, mass effect, or refractory

### **Clinical Pearls:**
- **Amphotericin B + flucytosine × 2 weeks** (induction) → **fluconazole 400mg × 8 weeks** (consolidation) → **200mg** (maintenance)
- **Manage ↑ICP aggressively:** Therapeutic LPs (goal <20 cm H2O), repeat daily if needed
- **Serum/CSF CrAg:** Gold standard (>95% sensitive)
- **Start ART 4-6 weeks after** antifungal therapy (reduce IRIS risk)
- **Fluconazole maintenance:** Until CD4 >200 × 6 months (HIV) OR ≥12 months (non-HIV)
- **NO steroids** for ↑ICP (worsen outcomes)

## Sources

- [IDSA: Cryptococcosis Guidelines 2024]
- [WHO: Cryptococcal Meningitis Management 2024]

## Media

N/A
